Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Chinese Medicine Group Co Days Payable Chart
HKSE:01643 vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Modern Chinese Medicine Group Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modern Chinese Medicine Group Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Modern Chinese Medicine Group Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Modern Chinese Medicine Group Co's Days Payable falls into.
Modern Chinese Medicine Group Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Chinese Medicine Group Co (HKSE:01643) has a Days Payable of 41.42 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Modern Chinese Medicine Group Co and its competitors. This is 27% below median its historical median of 56.36. Over the past decade, Modern Chinese Medicine Group Co's Days Payable has ranged from 49.49 to 121.21. According to the industry distribution chart, Modern Chinese Medicine Group Co ranks #596 out of 926 companies in the Drug Manufacturers industry, placing it in the top 64.4%.
Is Modern Chinese Medicine Group Co's Days Payable too high?
Modern Chinese Medicine Group Co's current Days Payable of 41.42 is 27% below median its 10-year median of 56.36. Over the past 10 years, this metric has ranged from a low of 49.49 to a high of 121.21. The Drug Manufacturers industry median Days Payable is 90.22. Modern Chinese Medicine Group Co's value of 41.42 is 54.1% below this industry median. Based on the distribution chart, Modern Chinese Medicine Group Co ranks #596 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Modern Chinese Medicine Group Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Modern Chinese Medicine Group Co's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Modern Chinese Medicine Group Co ranks #596 out of 926 companies for Days Payable. This places Modern Chinese Medicine Group Co in the lower half of its industry. The industry median Days Payable is 90.22. Modern Chinese Medicine Group Co's value of 41.42 is 54.1% below this benchmark. Historically, Modern Chinese Medicine Group Co's own Days Payable has ranged from 49.49 to 121.21 over the past decade. While the company's 10-year median is 56.36 vs. the industry median of 90.22, Modern Chinese Medicine Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Modern Chinese Medicine Group Co's current Days Payable of 41.42 is 54.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Modern Chinese Medicine Group Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modern Chinese Medicine Group Co's current Days Payable is 41.42, which is 27% below median its own 10-year median of 56.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modern Chinese Medicine Group Co stock overvalued right now?
Based on GuruFocus' analysis, Modern Chinese Medicine Group Co (HKSE:01643) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.16, compared to a current price of HK$0.94 — trading 487.5% above its estimated fair value. The current Days Payable is 41.42, which is 27% below median its 10-year median of 56.36 and 54.1% below the Drug Manufacturers industry median of 90.22. Modern Chinese Medicine Group Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Modern Chinese Medicine Group Co (HKSE:01643), the current Days Payable is 41.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Modern Chinese Medicine Group Co (HKSE:01643) Overvalued in 2026?
Based on GuruFocus' analysis, Modern Chinese Medicine Group Co stock appears to be overvalued.
The current stock price of HK$0.94 is trading 487.5% above its estimated GF Value™ of HK$0.16.
GuruFocus considers Modern Chinese Medicine Group Co to be Significantly Overvalued.
Key valuation signals for HKSE:01643:
Days Payable: 41.42 (27% below median its 10-year median of 56.36)
GF Value™: HK$0.16 vs. price of HK$0.94 (487.5% above fair value)
Industry Position: 54.1% below the Drug Manufacturers median (#596 of 926)
No single metric tells the full story. See the HKSE:01643 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Modern Chinese Medicine Group Co Business Description
Modern Chinese Medicine Group Co Ltd is engaged in the production of Proprietary Chinese Medicines. It offers both OTC and prescribed medicines intended for use by the Middle-aged and the Elderly in the PRC. Its products include liver protection tablets, Shanmei capsules, Qi and blood supplement pills, and Xiaohuoluo pills, among others. Geographically, the company derives its key revenue from the People's Republic of China.
53GF Score
Get the complete analysis for HKSE:01643
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01643 has been successfully added to your 
